Merck KGAA Courts US, China Investors To Accelerate Immuno-Oncology Development
Executive Summary
EMD Serono Inc.'s Head of BioPharma External Innovation Ravi Kiron outlines to Brian Yang how the Merck KGAA Group is courting US and Chinese Investors to fund such projects with a size of $100-200m.
You may also be interested in...
Forty Seven's IO Antibody Attracts Two Big Pharma Partners
Forty Seven Inc. has signed immuno-oncology deals with Merck of Germany and Roche that will see the launch of several combination studies for their PD-L1 inhibitors and Forty Seven's promising investigational CD47 antibody.
Hengrui, Affiliate Reistone In Apparent Dispute Over China Ivarmacitinib NDAs
The future fate of Jiangsu Hengrui’s new drug discovery and development subsidiary may provide some tips on what’s ahead for the Chinese biopharma sector.
ADCs Propel China Oncology Innovation But PD-1s Still Cast Shadow
Among the newer modalities to tackle cancer, antibody-drug conjugates are fast emerging to rival targeted antibodies and China is fast emerging as a world class source of innovation in the field, as evidenced by a string of recent deals.